

First Investment: 2019
For many disease-causing proteins, there are no known classical binding sites, so there’s been no way to develop small-molecule drugs to intervene. Frontier uses quantitative proteomics and machine learning to find pockets where small molecules can bind covalently, opening up formerly undruggable targets such as KRAS, a molecular switch driving many forms of cancer.
Explore Companies

Grove Biopharma
Putting protein-like drugs inside cells to fight cancer and neurodegeneration

Syntax Bio
Programming stem cells to differentiate into desired cell types, faster

Fable Therapeutics
Using state-of-the-art machine learning models to create custom-build protein drugs

Nilo Therapeutics
Mapping the brain-body axis to achieve proper immune balance